Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.

Nelson, Blessie Elizabeth; Meric-Bernstam, Funda

Nelson, Blessie Elizabeth; Meric-Bernstam, Funda.

Afiliación

Nelson BE; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; email: fmeric@mdanderson.org.
Meric-Bernstam F; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; email: fmeric@mdanderson.org.

Annu Rev Med ; 75: 31-48, 2024 Jan 29.

Article en En | MEDLINE | ID: mdl-37758237

RESUMEN

Antibody-drug conjugates (ADCs) have become the cornerstone of effective therapeutics in solid and hematological malignancies by harnessing potent cytotoxic payloads with targeted tumoricidal delivery. Since the monumental shift occurred with HER2-targeted ADCs, the discovery of the TROP2 antigen has revolutionized the landscape of ADC development. Moving beyond the traditional ADC design, multiple novel ADCs have successfully shaped and improved survival outcomes in patients with various tumor histologies. Here we review and contrast the clinical impact of the well-known TROP2 ADCs currently in clinical use. We also shed light on upcoming investigational TROP2 ADCs showing promise with novel ADC platforms.

Asunto(s)

Antineoplásicos; Neoplasias Hematológicas; Inmunoconjugados; Neoplasias; Humanos; Inmunoconjugados/uso terapéutico; Neoplasias/terapia; Antineoplásicos/uso terapéutico

Palabras clave

ADC; TROP2; antibody-drug conjugates; datopotamab; sacituzumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoconjugados / Neoplasias Hematológicas / Neoplasias / Antineoplásicos Límite: Humans Idioma: En Revista: Annu Rev Med Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google